Latham & Watkins Digest Tracks June 2026 Drug Pricing and Rebate Developments
Latham & Watkins LLP published its third June 2026 digest tracking developments in drug pricing policy, including the Medicaid Drug Rebate Program, 340B Program, Medicare reforms, and state-level legislative activity. The digest compiles recent regulatory actions, guidance, and policy changes affecting pharmaceutical pricing and market access. The publication serves as an ongoing reference for tracking federal and state drug pricing policy developments. This tracker does not report a single new event but aggregates multiple developments from the period.
Medicaid managed care organizations with pharmacy benefits must monitor Medicaid Drug Rebate Program changes and 340B policy to manage formularies, capitation rate negotiations, and supplemental rebate agreements with manufacturers.
Pharmacy · Managed Care
You might also like